Increased B Cell-Activating Factor Promotes Tumor Invasion and Metastasis in Human Pancreatic Cancer

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Koizumi, Mitsuhito ^a   Hiasa, Yoichi ^a   Kumagi, Teru ^a   Yamanishi, Hirofumi ^a   Azemoto, Nobuaki ^a   Kobata, Tetsuji ^b   Matsuura, Bunzo ^a   Abe, Masanori ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CELL INVASION; CELL MOTILITY; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MALE; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; PROTEIN BLOOD LEVEL; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; B-CELL ACTIVATING FACTOR; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84881120542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071367     Document Type: Article

References (39)

1. Wray CJ, Ahmad SA, Matthews JB, Lowy AM, (2005) Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128: 1626-1641.
2. Jemal A, Siegel R, Wu J, Ward E, (2010) Cancer Statistics 2010. CA Cancer J Clin 60: 277-300.
3. Philip PA, Benedetti J, Corless CL, Wong R, O′Reilly EM, et al. (2010) Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28: 3605-3610.
4. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19): 1817-1825.
5. Yamanishi H, Kumagi T, Yokota T, Azemoto N, Koizumi M, et al. (2011) Clinical significance of B cell-activating factor in autoimmune pancreatitis. Pancreas 40: 840-845.
6. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, et al. (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285: 260-263.
7. Mackay F, Schneider P, (2009) Cracking the BAFF code. Nat Rev Immunol 9: 491-502.
8. Chu VT, Enghard P, Riemekasten G, Berek C, (2007) In vitro and in vivo activation induces BAFF and APRIL expression in B cells. J Immunol 179: 5947-5957.
9. Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, et al. (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293: 2108-2111.
10. Von Bülow GU, Bram RJ, (1997) NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278: 138-141.
11. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, et al. (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404: 995-999.
12. Hahne M, Kataoka T, Schröter M, Hofmann K, Irmler M, et al. (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188: 1185-1190.
13. Hatzoglou A, Roussel J, Bourgeade MF, Rogier E, Madry C, et al. (2000) TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol 165: 1322-1330.
14. Shu HB, Johnson H, (2000) B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. Proc Natl Acad Sci USA 97: 9156-9161.
15. Yan M, Marsters SA, Grewal IS, Wang H, Ashkenazi A, Dixit VM, (2000) Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol 1: 37-41.
16. Kern C, Cornuel JF, Billard C, Tang R, Rouillard D, et al. (2004) Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 103: 679-688.
17. Moreaux J, Veyrune JL, De Vos J, Klein B, (2009) APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer 9: 83.
18. Zhu J, Sun L, Lin S, Zhao R, Zhou L, et al. (2012) BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells. J Exp Clin Cancer Res 31: 31.
19. Takahashi M, Furihata M, Akimitsu N, Watanabe M, Kaul S, et al. (2008) A highly bone marrow metastatic murine breast cancer model established through in vivo selection exhibits enhanced anchorage-independent growth and cell migration mediated by ICAM-1. Clin Exp Metastasis 25: 517-529.
20. Nakamura N, Hase H, Sakurai D, Yoshida S, Abe M, et al. (2005) Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch 447: 53-60.
21. Parameswaran R, Müschen M, Kim YM, Groffen J, Heisterkamp N, (2010) A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 70: 4346-56.
22. Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G, (1975) Establishment of a continuous tumor-cell line (panc-1) from a human carcinoma of the exocrine pancreas. Int J Cancer 15: 741-747.
23. Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, et al. (2008) BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 111: 2744-2754.
24. Moisini I, Davidson A, (2009) BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 158: 155-163.
25. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756.
26. Nakajima K, Itoh K, Nagatani K, Okawa-Takatsuji M, Fujii T, et al. (2007) Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 36: 365-372.
27. Mackay F, Leung H, (2006) The role of the BAFF/APRIL system on T cell function. Semin Immunol 18: 284-289.
28. Claudio E, Brown K, Park S, Wang H, Siebenlist U, (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol 3: 958-965.
29. Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM, Zhou BP, (2009) Stabilization of snail by NF-kappa B is required for inflammation-induced cell migration and invasion. Cancer Cell 15: 416-428.
30. Christiansen JJ, Rajasekaran AK, (2006) Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326.
31. Olmeda D, Jorda M, Peinado H, Fabra A, Cano A, (2007) Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene 26: 1862-1874.
32. Peinado H, Olmeda D, Cano A, (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415-428.
33. Cano A, Pérez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, et al. (2000) The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83.
34. Yilmaz M, Christofori G, (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28: 15-33.
35. Thieri JP, (2002) Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer 2: 442-454.
36. Petersen OW, Nielsen HL, Gudjonsson T, Villadsen R, Rank F, et al. (2003) Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 162: 391-402.
37. Dennis GJ, (2012) Belimumab: BLyS-specific inhibitor for the treatment of systemic lupus erythematosus. Clin Pharmacol Ther 91: 143-149.
38. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
39. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806.